Biodesix (BDSX) Cost of Revenue (2019 - 2026)

Biodesix has reported Cost of Revenue for 8 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 13.56% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (up 76.54% YoY), and the FY2025 full-year result was $7.6 million, changed 0.16% from the prior year.
• Cost of Revenue for Q1 2026 stood at $4.2 million, up from $2.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $4.2 million in Q1 2026, with the low at -$3.7 million in Q4 2024.
• Historically, Cost of Revenue has averaged $3.0 million across 5 years, with a median of $3.4 million in 2023.
• Annual changes were most pronounced in 2024 — Cost of Revenue tumbled 208.39% — and 2025, when it surged 153.62%.
• Biodesix's Cost of Revenue stood at $3.3 million in 2022, then increased by 2.06% to $3.4 million in 2023, then plunged by 208.39% to -$3.7 million in 2024, then soared by 153.62% to $2.0 million in 2025, then jumped by 114.43% to $4.2 million in 2026.
• The last three Cost of Revenue figures came in at $4.2 million (Q1 2026), $2.0 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.